A novel non-toxic camptothecin formulation for cancer chemotherapy
A novel non-toxic camptothecin formulation for cancer chemotherapy
复制标题
DOI：
10.1016/j.biomaterials.2004.06.013
复制
发表时间：
2005-05-01
期刊：
影响因子：
14
通讯作者：
Lehnert, S
中科院分区：
文献类型：
--
作者：
Berrada, M;Serreqi, A;Lehnert, S
描述了一种新型的可注射、生物相容和可生物降解的甲壳素聚合物植入物在肿瘤内持续释放高浓度喜树碱的方法。该药物载体是一种基于天然生物聚合物壳聚糖的原位热凝胶制剂。该制剂含有均匀分散的喜树碱。移植于小鼠皮下肿瘤模型(RIF-1)。治疗效果以肿瘤生长延迟(TGD)为指标。与未经治疗的动物以及通过腹腔注射系统注射喜树碱的动物相比，接受含有喜树碱的聚合物植入物治疗的动物的TGDS明显更长，而且没有体重减轻方面的毒性证据。结果表明，这种新型的可生物降解聚合物植入物是一种有效的喜树碱瘤内持续给药载体，也可能适用于其他不溶性抗癌药物如紫杉醇的给药。(C)2004爱思唯尔有限公司。保留所有权利。
The use of a novel injectable biocompatible and biodegradable caraptothecin-polymer implant for sustained intra-tumoral release of high concentrations of camptothecin is described. The drug delivery vehicle is an in situ thermogelling formulation, which is based on the natural biopolymer chitosan. This formulation, containing homogeneously dispersed camptothecin. was implanted intratumorally into a sub-cutaneous mouse tumor model (RIF-1). The effectiveness of treatment was measured in terms of tumor growth delay (TGD). Animals treated with the polymer implants containing camptothecin had significantly longer TGDs compared to untreated animals as well as to animals treated systemically with camptothecin by intra-peritoneal injection with no evidence of toxicity in terms of loss of body weight. The results indicate that this novel biodegradable polymer implant is an effective vehicle for the sustained intra-tumoral delivery of camptothecin which might also be suitable to deliver other insoluble anti-cancer drugs such as taxol. (C) 2004 Elsevier Ltd. All rights reserved.